SS Innovations International, Inc. announced that the Company has received regulatory approval for the SSi Mantra surgical robotic system (the ?SSi Mantra?), for multiple indications in Colombia, Oman, Sri Lanka and Kenya. The Company received regulatory approval for the SSi Mantra from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (?INVIMA?) in Colombia in November 2025, from the Directorate General of Pharmaceutical Affairs and Drug Control (?DGPA&DC?) in Oman in November 2025, from the National Medicines Regulatory Authority (?NMRA?) in Sri Lanka in January 2026, and from the Pharmacy and Poisons Board (?PPB?) in Kenya in January 2026. SS Innovations believes that it is favorably positioned to address these underpenetrated markets given the SSi Mantra?s cost advantages combined with its advanced technology, differentiated features, ease of training, and user-friendliness.
To date, the SSi Mantra has been granted regulatory approval in eleven countries, including India and the following: Colombia, Oman, Ecuador, Philippines, Guatemala, Sri Lanka, Indonesia, Ukraine, Kenya, United Arab Emirates.
